AI Market Mood: Stock Dashboard
PRME
Fundamental
Company: Prime Medicine Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -2.01
Insider Own: 61.20%
Shs Outstand: 131.16M
Perf Week: -11.11%
Market Cap: 367.25M
Forward P/E: -
EPS next Y: -1.22
Insider Trans: 0.00%
Shs Float: 50.89M
Perf Month: 0.72%
Income: -219.25M
PEG: -
EPS next Q: -0.38
Inst Own: 36.10%
Short Float: 33.82%
Perf Quarter: -31.37%
Sales: 0.80M
P/S: 459.06
EPS this Y: 26.60%
Inst Trans: -0.03%
Short Ratio: 15.90
Perf Half Y: -50.09%
Book/sh: 1.44
P/B: 1.94
EPS next Y Percentage: 24.04%
ROA: -76.67%
Short Interest: 17.21M
Perf Year: -58.76%
Cash/sh: 1.34
P/C: 2.09
EPS next 5Y: 20.17%
ROE: -114.35%
52W Range From: 2.56
52W Range To: 9.77
Perf YTD: -4.11%
Dividend Est.: -
P/FCF: -
EPS past 5Y: -193.88%
ROI: -96.90%
52W High: -71.34%
Beta: 1.86
Dividend TTM: -
Quick Ratio: 6.50
Sales past 5Y: -25.00%
Gross Margin: -607.25%
52W Low: 9.38%
ATR (14): 0.24
Dividend Ex-Date: Sep 10, 2019
Current Ratio: 6.50
EPS Y/Y TTM: -7.14%
Oper. Margin: -26598.50%
RSI (14): 43.67
Volatility W: 8.09%
Volatility M: 7.93%
Employees: 234
Debt/Eq: 0.22
Sales Y/Y TTM: -
Profit Margin: -27406.12%
Recom: 1.20
Target Price: 14.12
Option/Short: Yes / Yes
LT Debt/Eq: 0.19
EPS Q/Q: 20.58%
Payout: -
Rel Volume: 0.52
Prev Close: 2.83
Sales Surprise: -97.12%
EPS Surprise: -14.20%
Sales Q/Q: -
Earnings: Nov 12 AMC
Avg Volume: 1.08M
Price: 2.80
SMA20: -6.37%
SMA50: -7.55%
SMA200: -37.59%
Trades:
Volume: 565,089
Change: -1.06%
Technical:
Latest News:
Citigroup Upgrades Prime Medicine (PRME) - Nasdaq very bullish
PRME
Summary: Citigroup upgraded their outlook for Prime Medicine from Neutral to Buy with an analyst price forecast suggesting 114.11% upside. Various funds and institutions have reported positions in Prime Medicine, totaling 70,064K shares, with a bullish outlook indicated by the put/call ratio of 0.12.
Full article2024-05-17T22:16:55Z